Investors' Watch: Pomerantz Law Firm Investigates Larimar Therapeutics for Potential Securities Fraud

Investigating Larimar Therapeutics: A Closer Look at Investor Concerns

Pomerantz LLP, a leading law firm, has taken a significant step to protect the interests of investors in Larimar Therapeutics, Inc., publicly traded on NASDAQ under the symbol LRMR. The firm is actively investigating potential claims related to securities fraud and other unlawful business practices by the company and its management.

Larimar has recently come under scrutiny after issuing press releases that have raised eyebrows among investors. Notably, on September 29, 2025, the company shared data from a long-term open-label study focusing on the efficacy of daily subcutaneous injections of nomlabofusp, a treatment option for Friedreich's Ataxia. Despite branding this data as "positive," the announcement also disclosed that seven participants experienced anaphylaxis, a severe allergic reaction. This alarming news had a pronounced impact on Larimar’s stock price, which plummeted by $1.72 per share, equating to a staggering 33.66% decline, closing at $3.38.

Then, as recently as June 29, 2026, Larimar revealed further information from their ongoing study, stating they submitted the first section of their rolling Biologics License Application (BLA) for accelerated approval of nomlabofusp. While the press release again characterized the findings as "positive," it also confirmed that 10 out of 43 patients reported anaphylaxis, drawing attention to a significant ongoing safety concern. The market reacted swiftly, with the company's stock price dropping $0.46, or 12.57%, to close at $3.20.

The serious nature of these disclosures has caught the attention of legal experts at Pomerantz LLP. The firm is investigating whether Larimar and some of its senior management have engaged in misleading practices that could potentially harm shareholders. Investors who have suffered losses due to this situation are encouraged to reach out to Pomerantz attorney Danielle Peyton for guidance on their legal options.

Founded in the tradition of the late Abraham L. Pomerantz, who pioneered the securities class action practice over 85 years ago, Pomerantz LLP has earned a reputation for advocating fiercely for victims of corporate misconduct and securities fraud. With offices across the globe, including major cities like New York, Chicago, London, and Paris, the firm is viewed as one of the foremost authorities in corporate litigation today. The firm has successfully recovered numerous multi-million-dollar settlements for its clients, demonstrating its commitment to ensuring justice for investors.

With Larimar Therapeutics facing mounting legal scrutiny, investors should remain vigilant. The outcomes of these investigations could significantly influence their investments, and prompt action may be necessary. Remember, prior results in similar cases do not guarantee future outcomes, making it critical for investors to stay informed and proactive about their investments. For more information or to inquire about joining the ongoing investigation, contact Pomerantz LLP directly.

The Road Ahead

As Larimar navigates this turbulent phase, analysts and investors alike will be watching closely. The situation continues to evolve, and Pomerantz's investigation will clarify whether there any unlawful business practices committed by the company and its executives. Investors should stay tuned for updates and prepare for potential implications regarding their investments in Larimar.

As this story develops, Pomerantz LLP remains committed to fighting for the rights of investors in this proceeding, emphasizing the need for transparency and accountability in corporate practices.

For the latest updates and potential developments in Larimar Therapeutics’ situation, ensure to keep an eye on credible financial news sources and legal updates.